Cyclo Therapeutics Inc.

NAS: CYTH

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Cyclo Therapeutics Inc.

After Hours

--Quotes are delayed by 20 min

Jan 31, 2023, 7:35 p.m.

CYTH

/zigman2/quotes/207006339/composite

1.76

Change

0.00 0.00%

Volume

Volume 105

Quotes are delayed by 20 min

/zigman2/quotes/207006339/composite

Previous close

$ 1.68

$ 1.76

Change

+0.08 +4.76%

Day low

Day high

$1.65

$1.93

52 week low

52 week high

$0.91

$4.04

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Cyclo Therapeutics Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2017	2018	2019	2020	2021	5-year trend
Sales/Revenue	1.24M	1.01M	1.01M	903,376	1.59M
Sales Growth	-	-18.28%	-0.42%	-10.31%	75.54%
Cost of Goods Sold (COGS) incl. D&A	1.33M	1.29M	1.99M	2.64M	4.01M
COGS excluding D&A	1.32M	1.28M	1.98M	2.63M	3.99M
Depreciation & Amortization Expense	9,271	10,124	5,681	12,763	16,827
Depreciation	9,271	10,124	5,681	12,763	16,827
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	-2.91%	54.43%	32.87%	51.90%
Gross Income	(87,874)	(275,614)	(980,414)	(1.74M)	(2.43M)
Gross Income Growth	-	-213.65%	-255.72%	-77.22%	-39.60%
Gross Profit Margin	-	-	-	-	-152.96%	NA

	2017	2018	2019	2020	2021	5-year trend
SG&A Expense	3.75M	3.98M	6.41M	7.22M	11.86M
Research & Development	2.29M	2.71M	4.87M	6.1M	9.15M
Other SG&A	1.46M	1.27M	1.54M	1.13M	-
SGA Growth	-	6.03%	61.10%	12.69%	64.24%
Other Operating Expense	5,500	12,150	153,770	-	-
Unusual Expense	-	-	-	-	-
EBIT after Unusual Expense	-	-	-	-	-
Non Operating Income/Expense	2,820	-	-	-	-
Non-Operating Interest Income	10,261	11,773	12,027	19,802	3,405
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	-	-	-	-
Interest Expense Growth	-	-	-	-	-
Gross Interest Expense	-	-	-	-	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(3.83M)	(4.26M)	(7.53M)	(8.94M)	(14.29M)
Pretax Income Growth	-	-11.01%	-77.03%	-18.71%	-59.78%
Pretax Margin	-	-	-	-	-900.94%	NA
Income Tax	-	-	-	-	-
Income Tax - Current Domestic	-	-	-	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(3.83M)	(4.26M)	(7.53M)	(8.94M)	(14.29M)
Minority Interest Expense	-	-	-	-	-
Net Income	(3.83M)	(4.26M)	(7.53M)	(8.94M)	(14.29M)
Net Income Growth	-	-11.01%	-77.03%	-18.71%	-59.78%
Net Margin Growth	-	-	-	-	-900.94%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(3.83M)	(4.26M)	(7.53M)	(8.94M)	(14.29M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(3.83M)	(4.26M)	(7.53M)	(8.94M)	(14.29M)
EPS (Basic)	(5.00)	(0.05)	(6.96)	(5.59)	(2.24)
EPS (Basic) Growth	-	98.96%	-13,288.46%	19.69%	59.89%
Basic Shares Outstanding	720,372	81.76M	1.08M	1.6M	6.37M
EPS (Diluted)	(5.00)	(0.05)	(6.96)	(5.59)	(2.24)
EPS (Diluted) Growth	-	98.96%	-13,288.46%	19.69%	59.89%
Diluted Shares Outstanding	720,372	81.76M	1.08M	1.6M	6.37M
EBITDA	(3.84M)	(4.26M)	(7.54M)	(8.95M)	(14.27M)
EBITDA Growth	-	-10.94%	-77.11%	-18.70%	-59.50%
EBITDA Margin	-	-	-	-	-900.09%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Cyclo Therapeutics Inc.

Annual Financials for Cyclo Therapeutics Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk